AI in clinical trials has the potential to offer faster insights, greater efficiency, and improved data quality. Nowhere is this transformation more evident than in electronic data capture (EDC), where new AI-enabled tools are streamlining processes that have traditionally required intensive manual oversight. However, despite the momentum, adoption across the clinical industry can be slow or uneven.
Slow AI adoption in a risk-averse industry
Clinical trial operations have always prioritised reliability, regulatory compliance, and auditability. As a result, the industry has historically been cautious about adopting new technologies, with many organisations preferring proven, validated, and familiar systems, even when newer solutions offer clear efficiency gains.
AI innovation goes faster than ever before, and this caution risks holding organisations back. Clinical trials are becoming more complex, decentralised, and data-intensive, with teams under pressure to do more with fewer resources. AI offers a potential solution by automating routine tasks, identifying data anomalies faster and supporting smarter decision-making throughout the study lifecycle.
While many data managers express an interest in AI, they remain uncertain about how it fits into validated clinical environments and within established, often inflexible processes. Concerns include regulatory acceptance and whether AI tools will introduce new risks.
Another barrier is adoption rates. While there is much talk of AI, only a few vendors deliver AI-based functionalities that have a real impact. Empty promises made by technology vendors have left the industry wondering when AI will really make a difference to deliver on the hype.
Supporting successful AI adoption in clinical trials
AI functionalities can have a positive impact on processes and save considerable time and costs for clinical teams.
Ahead of the next wave of AI functionalities, CROs and sponsors should invest in change management and be ready to redefine the role of data managers and clinical data management processes. With an AI-automated EDC setup as an example, it is imperative that data managers adapt to being able to set up EDC in two days instead of ten weeks or longer.
The role of the data manager in this process should be evaluated, particularly if they transition from executor to validator. Other impacts need to be considered for how changes will affect other processes and stakeholders.
CRScube has undergone a significant transformation by evolving its software development processes to incorporate AI. The company emphasises practical implementation, suggesting that AI capabilities can be integrated into existing EDC and clinical data management frameworks rather than requiring organisations to overhaul existing processes.
This reduces adoption risk while enabling teams to benefit from automation in areas where it delivers the most operational value. In an industry where early negative experiences with AI can delay adoption, this targeted approach is critical to building long-term confidence.
Looking ahead, AI adoption in EDC is likely to follow a familiar technology curve. Early adopters will continue to experiment with advanced use cases such as predictive site performance analytics and automated protocol deviation detection. Meanwhile, the broader industry will focus on practical, validated applications that support immediate operational challenges.
However, those using proven solutions with precise use cases stand to unlock significant advantages and run significantly more efficient clinical trials.
To find out more about the efficiencies enabled by CRScube’s targeted, purpose-built AI approach, download the document below or register for the upcoming webinar.
